In addition, there are results showing that memory CD4+ T cells can recognize neoantigens and may lead to cancer remission after immunomodulation in the hepatocellular carcinoma (HCC) microenvironment after treatment with sorafenib (16). This evidence concerns the gene CD4 and cancer.